BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Biotech catalysts in 2024-08
204 industry Phase 2/3 trial readout(s) and 40 FDA decision event(s). Readouts include completed (ACTUAL) and still-estimated primary completion dates in this month, any status.
FDA decision events
Trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2024-08 est. | P1/P2 | Talaris Therapeutics Inc. | NCT00498160 Induction of Donor Specific Tolerance in Recipients of Live Donor Kidney Allografts by Donor Stem Cell Infusion | Renal Failure | unknown | 38 |
| 2024-08 | P3 | Candel Therapeutics, Inc. CADL | NCT01436968 Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer | Prostate Cancer | active not recruiting | 711 |
| 2024-08 est. | P2 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | NCT04826107 Study of DP303c Injection in Patients With Advanced or Metastatic Gastric Cancer | Gastric Cancer | unknown | 196 |
| 2024-08 est. | P2 | Valo Health, Inc. | NCT05327855 Efficacy and Safety of OPL-0301 Compared to Placebo in Adults With Post-Myocardial Infarction (MI) | Myocardial Infarction | withdrawn | |
| 2024-08 est. | P2 | Valo Health, Inc. | NCT05393284 Phase 2 Spectra Study to Evaluate the Safety and Efficacy of OPL-0401 in Patients With Diabetic Retinopathy | Non-proliferative Diabetic Retinopathy; Proliferative Diabetic Retinopathy | unknown | 114 |
| 2024-08 est. | P2 | Ellipses Pharma | NCT05411679 EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer | Gastric Cancer; Small-cell Lung Cancer | withdrawn | |
| 2024-08 est. | P1/P2 | Eledon Pharmaceuticals ELDN | NCT05480657 Safety, Tolerability, and Efficacy of Immunomodulation With AT-1501 in Combination With Transplanted Islet Cells in Adults With Brittle T1D | Brittle Type 1 Diabetes Mellitus | withdrawn | |
| 2024-08 est. | P3 | Connect Biopharm LLC CNTB | NCT05614817 CBP-201 in Adolescent and Adult Patients With Moderate-to-severe Atopic Dermatitis | Atopic Dermatitis | withdrawn | |
| 2024-08 est. | P3 | Laboratorio Elea Phoenix S.A. | NCT05668650 Double-blind Study to Evaluate the PK, Efficacy, Safety and Immunogenicity of MB12 Versus Keytruda® in Stage IV NSCLC | Non Small Cell Lung Cancer Metastatic | unknown | 174 |
| 2024-08 est. | P1/P2 | Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. | NCT05728619 HTMC0435 and Temozolomide in Treating Patients With Small Cell Lung Cancer | Recurrent Extensive Stage Small Cell Lung Carcinoma | unknown | 64 |
| 2024-08 est. | P1/P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT05783921 A Clinical Trial of TQB2618 Injection Combined With Penpulimab Injection and Chemotherapy Versus Penpulimab Injection Combined With Chemotherapy in First-line T | Recurrent Squamous Cell Carcinoma of the Head and Neck; Metastatic Squamous Cell Carcinoma | unknown | 60 |
| 2024-08 est. | P3 | Marinus Pharmaceuticals | NCT05814523 To Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ganaxolone Added to Standard of Care in Refractory Status Epilepticus (RSE) | Refractory Status Epilepticus | withdrawn | |
| 2024-08 est. | P3 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT05862337 Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence. | Hepatocellular Carcinoma | recruiting | 480 |
| 2024-08 est. | P2 | Constant Therapeutics LLC | NCT06013839 TXA127 in Non-Ambulant Patients With DMD Cardiomyopathy | DMD-Associated Dilated Cardiomyopathy | unknown | 10 |
| 2024-08 est. | P1/P2 | Biocity Biopharmaceutics Co., Ltd. | NCT06111326 BC3402 in Combination With Durvalumab in Patients With Advanced Hepatocellular Carcinoma | Hepatocellular Carcinoma | unknown | 83 |
| 2024-08 est. | P2 | Glaukos Corporation GKOS | NCT06152861 Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension | Open Angle Glaucoma; Ocular Hypertension | unknown | 250 |
| 2024-08-01 est. | P2 | Promontory Therapeutics Inc. | NCT02266745 A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and | Advanced Solid Tumors; CRPC; mCRPC; Metastatic Castrate-resistant Prostate Cancer; PT-112; Prostatic | unknown | 109 |
| 2024-08-01 | P1/P2 | Taiho Oncology, Inc. | NCT03520075 Study of ASTX029 in Subjects With Advanced Solid Tumors | Solid Tumor, Adult | completed | 192 |
| 2024-08-01 | P2 | Ascentage Pharma Group Inc. AAPG | NCT04126681 A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase | Chronic Myeloid Leukemia, Chronic Phase | completed | 144 |
| 2024-08-01 | P3 | Sanofi SNY | NCT04180488 Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naïve to, Intole | Chronic Spontaneous Urticaria | completed | 397 |
| 2024-08-01 est. | P2 | Celltex Therapeutics Corporation | NCT04448106 Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) for Osteoarthritis | Osteoarthritis, Knee; Osteoarthritis, Hip; Osteoarthritis Shoulder | unknown | 300 |
| 2024-08-01 | P2 | Cereno Scientific AB | NCT05224531 Effect of CS1 in Subjects With Pulmonary Arterial Hypertension | Pulmonary Arterial Hypertension | completed | 25 |
| 2024-08-01 | P1/P2 | Anaveon AG | NCT05578872 A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1). | Melanoma (Skin); Cutaneous Melanoma; Adult Disease; Advanced Solid Tumor; Metastatic Melanoma | completed | 29 |
| 2024-08-01 | P2/P3 | Boehringer Ingelheim | NCT05819398 Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa | Hidradenitis Suppurativa | completed | 209 |
| 2024-08-01 | P2 | Otsuka Beijing Research Institute | NCT05923892 Phase II Clinical Trial of OPS-2071 in the Treatment of Irritable Bowel Syndrome of Diarrhea Type | Irritable Bowel Syndrome of Diarrhea Type (IBS-D) | completed | 87 |
| 2024-08-01 | P2 | Arbutus Biopharma Corporation ABUS | NCT06245291 Study of Imdusiran (AB-729) in Combination With Intermittent Dosing of Durvalumab in Subjects With Chronic HBV Infection | Hepatitis B, Chronic | withdrawn | |
| 2024-08-01 est. | P2 | JKT Biopharma Co., Ltd. | NCT06288893 SHEN211 Tablets for the Treatment of Mild and Moderate Novel Corona Virus Infections (COVID-19) | COVID-19 | unknown | 30 |
| 2024-08-02 | P3 | GE Healthcare | NCT04265209 [18F] LBT-999 PET Compared to [123I]-FP/CIT SPECT to Distinguish Between Parkinson's Diseases and Essential Tremor | Parkinson Disease; Essential Tremor | completed | 152 |
| 2024-08-02 | P3 | Curium US LLC | NCT05204927 177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer | Metastasis From Malignant Tumor of Prostate | active not recruiting | 439 |
| 2024-08-02 est. | P1/P2 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | NCT05381662 CD19 Chimeric Antigen Receptors and CD19 Positive Feeder T Cells as a Leukemia Consolidation Treatment | Acute Lymphoblastic Leukemia in Remission | unknown | 10 |
| 2024-08-02 | P3 | Corxel Pharmaceuticals | NCT05410860 Efficacy and Safety Study of Etripamil Nasal Spray Self-Administration for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia | Tachycardia, Supraventricular; Paroxysmal Supraventricular Tachycardia | completed | 500 |
| 2024-08-02 | P2 | Novartis Pharmaceuticals NVS | NCT05462990 A Proof-of-concept Study to Examine QUC398 in Participants With Knee OA | Osteoarthritis, Knee | terminated | 101 |
| 2024-08-02 | P2 | GH Research Ireland Limited | NCT05804708 Phase 2 Clinical Trial of GH001 in Postpartum Depression | Postpartum Depression; Postnatal Depression | terminated | 10 |
| 2024-08-05 | P2 | Janssen Research & Development, LLC | NCT03842189 A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Pregnant Women at High Risk for Early Onset Severe Hemol | Hemolytic Disease of the Fetus and Newborn | completed | 25 |
| 2024-08-05 | P2 | MedPacto, Inc. | NCT04515979 Vactosertib in Combination with Pembrolizumab for PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) Subjects | Carcinoma, Non-Small-Cell Lung | terminated | 11 |
| 2024-08-05 | P3 | AstraZeneca AZN | NCT04924608 Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas | Neurofibromatosis 1; Plexiform Neurofibroma (PN) | active not recruiting | 145 |
| 2024-08-05 | P3 | GlaxoSmithKline | NCT04937387 Efficacy and Safety of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Chinese Participants With Inadequately Controlled Asthma | Asthma | completed | 359 |
| 2024-08-05 | P3 | Novo Nordisk A/S NVO | NCT05330325 A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow | SGA, Turner Syndrome, Noonan Syndrome, ISS | active not recruiting | 412 |
| 2024-08-05 | P3 | Insud Pharma | NCT05461573 Efficacy, Safety, and Tolerability of LPRI-CF113 as an Oral Contraceptive in Females | Contraception; Change in Bone Mineral Density | completed | 1542 |
| 2024-08-05 | P3 | Takeda TAK | NCT05529992 A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher Disease | Gaucher Disease | completed | 20 |
| 2024-08-05 | P2/P3 | Advagene Biopharma Co. Ltd. | NCT05541510 Evaluating the Safety and Efficacy of AD17002 Intranasal Spray in Treating Participants With Mild to Moderate COVID-19 | COVID-19 | terminated | 180 |
| 2024-08-05 | P2 | argenx ARGX | NCT05810961 A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Primary Membranous Nephropathy (ZL-1103-014) | Membranous Nephropathy | terminated | 8 |
| 2024-08-05 | P2/P3 | Laurent Pharmaceuticals Inc. | NCT05999435 Study of LAU-7b for the Treatment of Long COVID in Adults | Long COVID | completed | 272 |
| 2024-08-05 | P2 | Beijing InnoCare Pharma Tech Co., Ltd. | NCT06109818 Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients with Moderate to Severe Plaque Psoriasis | Moderate to Severe Plaque Psoriasis | completed | 129 |
| 2024-08-05 | P3 | Colgate Palmolive CL | NCT06427499 The Clinical of Stannous Fluoride Toothpaste and a Newly Designed Toothbrush Compared to Colgate Cavity Protection Toothpaste and a Regular Toothbrush in Reduci | Plaque; Gingivitis | completed | 95 |
| 2024-08-05 | P1/P2 | PT. JES Kasih Nusantara Sejahterah | NCT06866158 Autologous Dendritic Cell as Adjunct Therapy for Diabetic Kidney Disease | Diabetic Kidney Disease (DKD) | active not recruiting | 80 |
| 2024-08-06 | P3 | AstraZeneca AZN | NCT04157335 Efficacy and Safety Study of Benralizumab in Patient With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID) | Nasal Polyposis; Eosinophilic Chronic Rhinosinusitis | terminated | 295 |
| 2024-08-06 | P2 | UCB Biopharma SRL | NCT04519645 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Lacosamide in Neonates With Repeated Electroencephalographic Neonatal Seizures | Electroencephalographic Neonatal Seizures; Epilepsy | terminated | 29 |
| 2024-08-06 | P2 | Imbria Pharmaceuticals, Inc. | NCT04826159 IMPROVE-DiCE: Study to Evaluate Effect of IMB-1018972 on Cardiac Energetics in T2DM & Obesity (Pt 1) With HFpEF (Pt 2) | Type 2 Diabetes; Diabetic Cardiomyopathies; HFpEF - Heart Failure With Preserved Ejection Fraction | completed | 49 |
| 2024-08-06 | P2 | Tempus AI TEM | NCT05169437 Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors | Solid Tumor; Breast Tumor; Colon Tumor, Malignant; Lung Tumor; Urologic Cancer; Pancreatic Cancer; M | terminated | 22 |
| 2024-08-06 | P2 | Bristol-Myers Squibb BMY | NCT05730725 A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis | Psoriasis | completed | 109 |
| 2024-08-06 | P2 | AbbVie ABBV | NCT05771428 Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild A | Alzheimer's Disease (AD) | completed | 263 |
| 2024-08-07 | P1/P2 | BioMarin Pharmaceutical BMRN | NCT03520712 Gene Therapy Study in Severe Hemophilia A Patients With Antibodies Against AAV5 | Hemophilia A; Gene Therapy; Clotting Disorders; Blood Disorder | terminated | 3 |
| 2024-08-07 | P3 | Novartis Pharmaceuticals NVS | NCT04873934 Management of LDL-cholesterol With Inclisiran + Usual Care Compared to Usual Care Alone in Participants With a Recent Acute Coronary Syndrome | Acute Coronary Syndrome | completed | 400 |
| 2024-08-07 | P2 | Guangdong Hengrui Pharmaceutical Co., Ltd | NCT05722964 Study on Intravenous Injection of SHR-1906 in the Treatment of Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | completed | 30 |
| 2024-08-07 | P3 | Kowa Company, Ltd. | NCT05923281 A Phase III Confirmatory Study of K-877 (Pemafibrate) in Patients With Hypercholesterolemia and Statin Intolerance | Hypercholesterolemia | completed | 71 |
| 2024-08-07 | P3 | R-Pharm | NCT06320353 Study сomparing the Efficacy and Safety of RPH-075 and Keytruda® in Patients With Unresectable or Metastatic Skin Melanoma | Skin Melanoma | completed | 266 |
| 2024-08-08 | P2 | Novartis Pharmaceuticals NVS | NCT04097379 Safety, Tolerability and Preliminary Efficacy of Multiple Intra-articular Injections of LRX712 in Patients With Knee OA | Osteoarthritis (OA) | completed | 45 |
| 2024-08-08 | P3 | GlaxoSmithKline | NCT04133909 Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level | Pulmonary Disease, Chronic Obstructive | completed | 806 |
| 2024-08-08 | P3 | Aerovate Therapeutics | NCT05557942 Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial - Follow Up Long Term Extension (IMPAHCT-FUL) | Pulmonary Arterial Hypertension | terminated | 186 |
| 2024-08-08 | P3 | Ionis Pharmaceuticals, Inc. IONS | NCT05610280 A Study of Olezarsen (ISIS 678354) in Participants With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease, or With Severe Hypertriglyceridemia | Hypertriglyceridemia; Cardiovascular Diseases; Atherosclerosis | completed | 1478 |
| 2024-08-08 | P2 | InSilico Medicine Hong Kong Limited | NCT05938920 Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis (IPF) | completed | 71 |
| 2024-08-08 | P2 | Bristol-Myers Squibb BMY | NCT06094296 A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) | NSCLC | terminated | 1 |
| 2024-08-09 | P2 | Ascletis Pharmaceuticals Co., Ltd. | NCT04465890 A Phase II Study of Subcutaneously Injected PD-L1 Antibody ASC22 in Chronic Hepatitis B Patients | Chronic Hepatitis b | completed | 207 |
| 2024-08-09 | P2/P3 | Aerovate Therapeutics | NCT05036135 A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH) | Pulmonary Arterial Hypertension | terminated | 202 |
| 2024-08-09 | P1/P2 | Nanjing Leads Biolabs Co.,Ltd | NCT05223231 Evaluation of LBL-019 Monotherapy or Combined With Anti-PD-1 Antibody in the Treatment of Advanced Malignant Tumors | Advanced Malignant Tumors | completed | 26 |
| 2024-08-09 est. | P2 | Hrain Biotechnology Co., Ltd. | NCT05436223 Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma | B-cell Non-Hodgkin's Lymphoma | unknown | 100 |
| 2024-08-09 | P2/P3 | Ascendis Pharma Growth Disorders A/S ASND | NCT05598320 A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Children With Achondroplasia | Achondroplasia | completed | 84 |
| 2024-08-09 | P3 | Eli Lilly and Company LLY | NCT05767021 A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis | Ulcerative Colitis; Ulcerative Colitis Chronic | completed | 172 |
| 2024-08-09 | P2 | Dexa Medica Group | NCT06127225 Proliverenol Supplementation for Non-Alcoholic Fatty Liver Disease (NAFLD) | Non-Alcoholic Fatty Liver Disease (NAFLD) | completed | 80 |
| 2024-08-09 | P2/P3 | Chengdu Suncadia Medicine Co., Ltd. | NCT07844356 The Safety and Efficacy of HR19034 in Children With Myopia | Slowing the Progression of Myopia in Children | completed | 509 |
| 2024-08-11 | P2 | Hunazine Biotech S.L. | NCT06193408 Assessment of a Novel Fixed-dose Combination (FDC) Drug VR-AD-1005 for the Treatment of Acute Watery Diarrhea in Cholera | Cholera | completed | 150 |
| 2024-08-12 | P3 | Pharmicell Co., Ltd. | NCT01652209 To Evaluate the Efficacy and Safety of Hearticelgram®-AMI in Patients With Acute Myocardial Infarction. | Acute Myocardial Infarction | completed | 90 |
| 2024-08-12 | P3 | Biogen BIIB | NCT03070119 Long-Term Evaluation of BIIB067 (Tofersen) | ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation | completed | 139 |
| 2024-08-12 | P2 | Hanmi Pharmaceutical Company Limited HAFC | NCT04768686 FLX475 Combined With Pembrolizumab in Patients With Advanced or Metastatic Gastric Cancer | Gastric Cancer | completed | 20 |
| 2024-08-12 | P2 | Syros Pharmaceuticals | NCT04905407 Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia | terminated | 66 |
| 2024-08-12 | P1/P2 | Ascentage Pharma Group Inc. AAPG | NCT04946864 A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer | Breast Cancer; Solid Tumor, Adult | suspended | 65 |
| 2024-08-12 | P3 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT05179239 A Study of SHR-1701 Plus Platinum-containing Chemotherapy With or Without BP102 (Bevacizumab) as First-line Treatment in Cervical Cancer | Cervical Cancer | terminated | 31 |
| 2024-08-12 | P3 | Biogen BIIB | NCT05310071 A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease | Alzheimer's Disease | terminated | 1027 |
| 2024-08-12 | P2 | AstraZeneca AZN | NCT05492877 An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD. | Chronic Obstructive Pulmonary Disease (COPD) | completed | 381 |
| 2024-08-12 | P2 | Bristol-Myers Squibb BMY | NCT05577715 A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) | Carcinoma, Non-Small-Cell Lung | terminated | 31 |
| 2024-08-12 | P1/P2 | Pfizer PFE | NCT05626322 Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma | Diffuse Large B-Cell Lymphoma | terminated | 6 |
| 2024-08-12 | P3 | Ellodi Pharmaceuticals, LP | NCT05634746 24-Week Induction Study of APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE 3) | Eosinophilic Esophagitis | completed | 218 |
| 2024-08-12 | P2 | GlaxoSmithKline | NCT05838742 A Dose-Finding Study to Evaluate the Efficacy and Safety of GSK3858279 in Adults With Knee Osteoarthritis (OA) Pain | Pain; Osteoarthritis, Knee | terminated | 314 |
| 2024-08-12 | P2 | Oneness Biotech Co., Ltd. | NCT05941793 A Study to Evaluate the Efficacy, Safety, and Concentration of SNS812 in Mild to Moderate COVID-19 Patients | Mild to Moderate COVID-19 | completed | 135 |
| 2024-08-12 | P2 | Prolacta Bioscience | NCT06102213 Study To Evaluate The Safety And Efficacy of PBCLN-010 In Combination With PBCLN-014 in Participants Receiving Allogeneic Hematopoietic Cell Transplantation | Hematologic Malignancy | terminated | 46 |
| 2024-08-13 | P3 | Hoffmann-La Roche | NCT04487067 A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma No | Carcinoma, Hepatocellular | completed | 152 |
| 2024-08-13 | P1/P2 | Biogen BIIB | NCT04494256 A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participan | Amyotrophic Lateral Sclerosis | terminated | 99 |
| 2024-08-13 | P2 | Novartis Pharmaceuticals NVS | NCT04546633 Efficacy, Safety and Tolerability of KAF156 in Combination With Lumefantrine Solid Dispersion Formulation (LUM-SDF) in Pediatric Population With Uncomplicated P | Uncomplicated Plasmodium Falciparum Malaria | completed | 295 |
| 2024-08-13 | P3 | Novartis Pharmaceuticals NVS | NCT04935359 Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) | Metastatic Pancreatic Ductal Adenocarcinoma | completed | 511 |
| 2024-08-13 | P2 | TBF Genie Tissulaire | NCT05199155 Use of a Nerve Regeneration Conduit (NerVFIX®) in the Treatment of Nerve Section of the Wrist | Nerve Injury; Nerve Lesion | terminated | 12 |
| 2024-08-13 | P2 | Arthrosi Therapeutics | NCT05253833 Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination With Allopurinol in Patients With Tophaceous Gout | Gout; Arthritis, Gouty; Hyperuricemia; Gout Chronic | completed | 42 |
| 2024-08-13 | P2 | Alumis Inc ALMS | NCT05953688 POC Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Active Intermediate, Posterior, or Pan NIU | Uveitis Posterior Non-Infectious; Uveitis, Intermediate; Noninfectious Panuveitis | terminated | 36 |
| 2024-08-13 | P2 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | NCT06118021 A Study of HS-20094 Evaluating Weight Loss in Obese and Overweight Chinese Subjects | Overweight and Obesity | completed | 200 |
| 2024-08-13 | P3 | Jiangsu HengRui Medicine Co., Ltd. | NCT06222294 A Study of Remimazolam Tosilate for Sedation in the ICU | Sedation in the ICU | completed | 214 |
| 2024-08-13 | P2 | Regor Pharmaceuticals Inc. | NCT06277934 A Study of RGT001-075 in Participants With Obesity or Overweight With Weight-Related Comorbidities | Obesity | completed | 73 |
| 2024-08-13 | P2 | G.ST Antivirals GmbH | NCT06375772 A Controlled Human Rhinovirus Infection Study of 2-Deoxy-D-Glucose in Healthy Adults | Acute Nasopharyngitis | terminated | 64 |
| 2024-08-13 | P2 | BrightGene Bio-Medical Technology Co., Ltd. | NCT06974825 A Study of BGM0504 in Chinese Patients With Type 2 Diabetes | Type 2 Diabetes | completed | 67 |
| 2024-08-14 | P3 | Novartis Pharmaceuticals NVS | NCT06149104 A Safety Study of Sacubitril/Valsartan in Japanese Pediatric Patients With Heart Failure Due to Systemic Left Ventricle Systolic Dysfunction Who Have Completed | Heart Failure | completed | 8 |
| 2024-08-14 | P3 | Takeda TAK | NCT06422377 A Study Evaluating Soticlestat in Participants With Dravet Syndrome or Lennox-Gastaut Syndrome Who Have Been Exposed to Fenfluramine | Dravet Syndrome (DS); Lennox-Gastaut Syndrome (LGS) | terminated | 1 |
| 2024-08-15 | P3 | Hoffmann-La Roche | NCT04221477 A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus Nephritis | Lupus Nephritis | active not recruiting | 271 |
| 2024-08-15 | P3 | Eisai Inc. | NCT04572243 A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome | Epilepsies, Myoclonic | terminated | 22 |
| 2024-08-15 | P1/P2 | Incyte Corporation INCY | NCT04582539 To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma | Myelodysplastic Syndromes; Multiple Myeloma; Anemia | terminated | 22 |
| 2024-08-15 est. | P3 | AO GENERIUM | NCT04667039 Efficacy, Safety, pharmacokinetiсs, Immunogenicity of GNR-067 and Lucentis® | Age Related Macular Degeneration (ARMD) | unknown | 408 |
| 2024-08-15 | P3 | Merck Sharp & Dohme LLC MRK | NCT05064059 A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Ca | Colorectal Cancer | completed | 441 |
| 2024-08-15 | P2 | AbbVie ABBV | NCT05227703 A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia | Schizophrenia | completed | 391 |
| 2024-08-15 | P3 | Grünenthal GmbH | NCT05449132 Comparison of a Single RTX-GRT7039 and Placebo Intra-articular Injection for Pain Associated With Osteoarthritis of the Knee | Osteoarthritis | completed | 466 |
| 2024-08-15 | P1/P2 | Hoffmann-La Roche | NCT05459129 A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morphe | Squamous Cell Carcinoma of the Head and Neck | completed | 12 |
| 2024-08-15 | P3 | Merck Sharp & Dohme LLC MRK | NCT05600309 A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Ca | Colorectal Cancer | completed | 94 |
| 2024-08-15 | P2 | argenx ARGX | NCT05918978 Open Label Extension of Efgartigimod in Adults With Post-COVID-19 POTS | Post-COVID Postural Orthostatic Tachycardia Syndrome Postural Orthostatic Tachycardia Syndrome | terminated | 33 |
| 2024-08-15 | P2/P3 | Kendal Nutricare Ltd | NCT06312059 Goat or Cow Milk Based Infant Formula GMS | Growth | completed | 409 |
| 2024-08-16 | P3 | Boehringer Ingelheim | NCT05321069 A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis | completed | 1177 |
| 2024-08-16 | P3 | Sunshine Lake Pharma Co., Ltd. SBFM | NCT05802862 A Study of Insulin Degludec/Insulin Aspart Biosimilar (22011) Compared With Insulin Degludec/Insulin Aspart(Ryzodeg) in Participants With Type 2 Diabetes in Chi | Diabetes | completed | 414 |
| 2024-08-18 est. | P2 | MimiVax, LLC | NCT05163080 SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE) | Newly Diagnosed Glioblastoma | unknown | 247 |
| 2024-08-18 | P2 | Navitor Pharmaceuticals, Inc. | NCT06235905 Open-Label of SPN-820 in Adults With Major Depressive Disorder | Major Depressive Disorder | completed | 40 |
| 2024-08-19 | P2 | Novartis Pharmaceuticals NVS | NCT04541589 Study of Safety and Tolerability of CFZ533 in Patients With Sjögren's Syndrome | Sjogren's Syndrome | completed | 206 |
| 2024-08-19 | P2 | Alector Inc. ALEC | NCT04592874 A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease | Alzheimer Disease | completed | 356 |
| 2024-08-19 | P2 | Enanta Pharmaceuticals, Inc ENTA | NCT04816721 A Study to Evaluate EDP 938 Regimens in Children With RSV | Respiratory Syncytial Virus (RSV) | completed | 99 |
| 2024-08-19 | P2 | GlaxoSmithKline | NCT05064358 Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma | Multiple Myeloma | completed | 177 |
| 2024-08-19 | P2 | Bristol-Myers Squibb BMY | NCT05556343 A Study to Evaluate the Efficacy, Safety, and Tolerability of MYK-224 in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy | Cardiomyopathy, Hypertrophic | terminated | 18 |
| 2024-08-19 | P2 | Vertex Pharmaceuticals Incorporated VERX | NCT05643495 A Study to Evaluate Efficacy and Safety of VX-864 in Participants With the PiZZ Genotype | Alpha-1 Antitrypsin Deficiency | terminated | 14 |
| 2024-08-19 | P2 | Kainos Medicine Inc. | NCT05695378 Trial to Evaluate the Efficacy and Safety of KM-819 Treatment to Slow the Progression of Multiple System Atrophy (MSA) | Multiple System Atrophy | terminated | 68 |
| 2024-08-19 | P3 | Novo Nordisk A/S NVO | NCT05891496 A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease | Alzheimers Disease | completed | 23 |
| 2024-08-19 | P1/P2 | Janssen Vaccines & Prevention B.V. | NCT05901636 A Clinical Study to Evaluate an Experimental Universal Influenza Vaccine, INFLUENZA G1 mHA, in Healthy Adults | Influenza Prevention | completed | 170 |
| 2024-08-19 | P3 | Corxel Pharmaceuticals | NCT06045299 Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia | Presbyopia; Near Vision; Miosis; Eye Diseases | completed | 300 |
| 2024-08-19 | P3 | Akeso | NCT06066125 A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Moderate to Severe Plaque Psoriasis | Psoriasis; Skin Diseases | completed | 351 |
| 2024-08-19 | P2 | Aligos Therapeutics ALGS | NCT06342947 ALG-055009 in Non-cirrhotic Adults With MASH (HERALD) | NASH; MASH; Metabolic Dysfunction-Associated Steatohepatitis; Nonalcoholic Steatohepatitis | completed | 102 |
| 2024-08-20 | P1/P2 | Shanghai EpimAb Biotherapeutics Co., Ltd. | NCT04735575 A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma | Relapsed or Refractory Multiple Myeloma | terminated | 40 |
| 2024-08-20 | P2 | Inversago Pharma Inc. | NCT05514548 Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease | Diabetic Kidney Disease | completed | 265 |
| 2024-08-20 | P2 | Bayer | NCT05526248 A Study Called ARAMON to Learn to What Extent Does Study Treatment With Darolutamide Affects Testosterone Levels in Men With Prostate Cancer That Had Not Been T | Biochemically Recurrent Prostate Cancer | completed | 28 |
| 2024-08-20 | P3 | Ipsen | NCT05590793 Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate | Advanced Prostate Cancer; Metastatic Prostate Cancer; Locally Advanced Prostate Cancer | completed | 195 |
| 2024-08-20 | P1/P2 | Shanghai Hengrui Pharmaceutical Co., Ltd. | NCT05794477 A Study of SHR-1802 in Combination With Adebrelimab in Patients With Advanced Solid Tumors | Advanced Solid Tumor | completed | 16 |
| 2024-08-20 | P2 | Clearside Biomedical, Inc. | NCT05891548 Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related Macular Degeneration | Neovascular Age-related Macular Degeneration | completed | 60 |
| 2024-08-20 | P2 | Qlaris Bio, Inc. | NCT06016972 Qlaris Phase 2 Study of QLS-111 in POAG And/or OHT Patients | Primary Open Angle Glaucoma (POAG); Primary Open Angle Glaucoma of Both Eyes; Primary Open-Angle Gla | completed | 63 |
| 2024-08-21 | P3 | Gilead Sciences GILD | NCT04925752 Pre-Exposure Prophylaxis Study of Lenacapavir in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People at Risk for HIV Infection | Pre-Exposure Prophylaxis of HIV Infection | active not recruiting | 3292 |
| 2024-08-21 | P3 | Kissei Pharmaceutical Co., Ltd. | NCT05440383 A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia | Uterine Fibroids (MeSH Heading: Leiomyoma) | completed | 287 |
| 2024-08-22 | P1/P2 | Amicus Therapeutics | NCT02675465 First-In-Human Study to Evaluate Safety, Tolerability, and PK of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221 | Pompe Disease | completed | 29 |
| 2024-08-22 | P1/P2 | Bristol-Myers Squibb BMY | NCT04349267 Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors | Advanced Solid Tumor | completed | 44 |
| 2024-08-22 | P1/P2 | Novartis Pharmaceuticals NVS | NCT04623216 Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation. | Acute Myeloid Leukemia | terminated | 24 |
| 2024-08-22 | P2 | Bristol-Myers Squibb BMY | NCT04857034 A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) | Lupus Erythematosus, Discoid; Lupus Erythematosus, Subacute Cutaneous | active not recruiting | 74 |
| 2024-08-22 | P3 | Apollomics Inc. APLM | NCT05054543 Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML | Relapsed/Refractory AML | terminated | 140 |
| 2024-08-22 | P2 | Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) | NCT05223920 An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-7289-CTP-202/MK-3543-005) | Thrombocythemia, Essential; Primary Myelofibrosis | completed | 81 |
| 2024-08-22 | P1/P2 | Bristol-Myers Squibb BMY | NCT05407675 A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced | Advanced Solid Tumors | completed | 68 |
| 2024-08-22 | P3 | Bond Avillion 2 Development LP | NCT05505734 A Comparison of PT027 vs PT007 Used as Needed in Participants With Asthma | Asthma | completed | 2516 |
| 2024-08-22 | P2 | Invirsa, Inc. | NCT05636228 Study of INV-102 Ophthalmic Solution in Adults With Acute Infectious Keratoconjunctivitis | Acute Infectious Keratoconjunctivitis | completed | 93 |
| 2024-08-22 | P2 | Sanofi SNY | NCT05849922 A Study to Test the Efficacy and Safety of SAR442970 in Adults With Hidradenitis Suppurativa | Hidradenitis Suppurativa | completed | 86 |
| 2024-08-22 | P2 | Bayer | NCT06112756 A Study to Learn About How Elinzanetant Works and How Safe it is in Women Having Sleep Disturbances Associated With Menopause | Sleep Disturbances Associated With Menopause | completed | 110 |
| 2024-08-23 | P2 | AstraZeneca AZN | NCT03778229 Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib | Carcinoma | active not recruiting | 367 |
| 2024-08-23 | P3 | Novo Nordisk A/S NVO | NCT03914326 A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes | Diabetes Mellitus, Type 2 | completed | 9651 |
| 2024-08-23 | P3 | Janssen Pharmaceutical K.K. | NCT05167825 A Study of Macitentan in Japanese Pediatric Participants With Pulmonary Arterial Hypertension | Pulmonary Arterial Hypertension | completed | 7 |
| 2024-08-23 | P2 | AbbVie ABBV | NCT05227690 A Trial of 10 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia | Schizophrenia | completed | 385 |
| 2024-08-23 | P3 | Jadran Galenski laboratorij d.d. | NCT07050446 Vizol S DIGI EYE Efficacy and Safety Study in Patients With Dry Eye | Dry Eye Disease (DED) | completed | 86 |
| 2024-08-24 | P3 | Viatris Specialty LLC VTRS | NCT06215820 Study of MR-107A-02 for the Treatment of Acute Postoperative Pain Following Bunionectomy | Acute Pain; Post Operative Pain; Pain | completed | 410 |
| 2024-08-25 | P3 | Colgate Palmolive CL | NCT06430060 Investigation of Colgate Dual Zinc Toothpaste as Compared to Colgate Cavity Protection Toothpaste in Controlling Plaque and Gingivitis | Plaque, Dental; Gingivitis | completed | 86 |
| 2024-08-26 | P2 | Pfizer PFE | NCT03709680 Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors | Ewing Sarcoma; Solid Tumors; Rhabdoid Tumor; Rhabdomyosarcoma; Neuroblastoma; Medulloblastoma; Diffu | completed | 128 |
| 2024-08-26 | P3 | Merck Sharp & Dohme LLC MRK | NCT03740165 Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated A | Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Neoplasms | completed | 1367 |
| 2024-08-26 | P3 | Antengene Corporation | NCT04939142 A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed | Relapsed or Refractory Multiple Myeloma | completed | 154 |
| 2024-08-26 | P2 | Genome & Company | NCT05419362 GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Gastric Cancer | Gastric Cancer; Gastroesophageal Junction Adenocarcinoma | completed | 42 |
| 2024-08-26 | P2 | Novartis Pharmaceuticals NVS | NCT05497284 To Assess the Efficacy of the Investigational Products Compared to Placebo in Participants With IPF | Idiopathic Pulmonary Fibrosis | terminated | 46 |
| 2024-08-26 | P3 | Novartis Pharmaceuticals NVS | NCT05513001 An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With | Chronic Spontaneous Urticaria | active not recruiting | 696 |
| 2024-08-26 | P2 | Adverum Biotechnologies, Inc. | NCT05536973 Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA] | Neovascular Age-related Macular Degeneration | active not recruiting | 69 |
| 2024-08-26 | P3 | Amgen AMGN | NCT05899816 A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER) | Atopic Dermatitis; Moderate-to-severe Atopic Dermatitis | completed | 221 |
| 2024-08-26 | P1/P2 | EyeBiotech Ltd. | NCT05919693 A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) | Neovascular Age-related Macular Degeneration (NVAMD); Diabetic Macular Edema (DME) | completed | 33 |
| 2024-08-26 | P2 | Hope Medicine (Nanjing) Co., Ltd | NCT06118866 A Study to Assess the Efficacy and Safety of HMI-115 in Male Subjects With Androgenetic Alopecia | Androgenetic Alopecia | completed | 192 |
| 2024-08-27 | P1/P2 | X4 Pharmaceuticals XFOR | NCT04154488 A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders | Neutropenia | completed | 32 |
| 2024-08-27 | P3 | Octapharma | NCT04508530 Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS/PANDAS) | Pediatric Acute-Onset Neuropsychiatric Syndrome | completed | 71 |
| 2024-08-27 | P3 | EMD Serono Research & Development Institute, Inc. | NCT05386550 Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION) | Head and Neck Cancer | terminated | 166 |
| 2024-08-27 | P3 | Valneva Austria GmbH | NCT06028841 A Clinical Phase 3 Trial of VLA1553 in Adult Participants with Human Immunodeficiency Virus (HIV) | Chikungunya Virus Infection | withdrawn | |
| 2024-08-27 | P2 | ViiV Healthcare | NCT06061081 A Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH3739937 in in Treatment-Naive Adults Living With HIV-1 | HIV Infections | terminated | 21 |
| 2024-08-28 | P3 | Actelion | NCT02932410 A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH) | Pulmonary Arterial Hypertension | completed | 165 |
| 2024-08-28 | P3 | Bristol-Myers Squibb BMY | NCT04008030 A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/M | Metastatic Colorectal Cancer | active not recruiting | 839 |
| 2024-08-28 | P1/P2 | BeiGene | NCT04282018 Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Follicular Lymphoma; Marginal Zone Lymphom | completed | 97 |
| 2024-08-28 | P2 | NeoImmuneTech | NCT04984811 NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC | Carcinoma, Non-Small-Cell Lung; Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma; Nonsmall | terminated | 33 |
| 2024-08-29 | P1/P2 | Bristol-Myers Squibb BMY | NCT03446040 An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread | Advanced Cancer | terminated | 92 |
| 2024-08-29 | P1/P2 | Nerviano Medical Sciences | NCT03922100 Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML | Acute Myeloid Leukemia (AML); Chronic Myelomonocytic Leukemia (CMML) | terminated | 63 |
| 2024-08-29 | P3 | Sanofi SNY | NCT04411641 Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES) | Non-relapsing Secondary Progressive Multiple Sclerosis | completed | 1131 |
| 2024-08-29 | P2 | PTC Therapeutics PTC | NCT05485987 A Study of Vatiquinone for the Treatment of Participants With Friedreich Ataxia | Friedreich Ataxia | completed | 5 |
| 2024-08-29 | P2 | D. Western Therapeutics Institute, Inc. | NCT05913232 Study of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension | Glaucoma Open-Angle Primary; Ocular Hypertension | completed | 201 |
| 2024-08-29 | P2/P3 | Xgene Pharmaceutical Group | NCT06017999 XG005 for Pain Control in Subjects Undergoing Bunionectomy | Acute Pain | completed | 450 |
| 2024-08-29 | P2 | Janssen Research & Development, LLC | NCT06028438 A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis | Arthritis, Rheumatoid | completed | 103 |
| 2024-08-30 | P3 | Bristol-Myers Squibb BMY | NCT03036098 Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participa | Urothelial Cancer | completed | 1314 |
| 2024-08-30 | P3 | EMS | NCT03527069 Efficacy and Safety of Cipros 10 Association on the Isolated Hypertriglyceridemia and Dyslipidemia Treatment | Hypertriglyceridemia; Dyslipidemia | completed | 146 |
| 2024-08-30 est. | P3 | Nanjing Yoko Biomedical Co., Ltd. | NCT04205565 Study on Clinical Effectiveness of L-Oxiracetam Injection | Craniocerebral Injury | unknown | 591 |
| 2024-08-30 | P1/P2 | Arcus Biosciences, Inc. RCUS | NCT04381832 Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer | Prostatic Neoplasms, Castration-Resistant; Androgen-Resistant Prostatic Neoplasms; Castration Resist | completed | 173 |
| 2024-08-30 | P1/P2 | BeiGene | NCT05267054 Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab | Relapsed Diffuse Large B-cell Lymphoma; Refractory Diffuse Large B-cell Lymphoma | completed | 53 |
| 2024-08-30 est. | P3 | Jiangsu HengRui Medicine Co., Ltd. | NCT05324631 A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Non-Radiographic Axial Spondyloarthritis | Non-radiographic Axial Spondyloarthritis | unknown | 300 |
| 2024-08-30 | P3 | Shionogi | NCT05897541 Phase 3 Study of S-217622 in Prevention of Symptomatic SARS-CoV-2 Infection | SARS-CoV-2 Infection | completed | 3701 |
| 2024-08-30 | P3 | Zensun Sci. & Tech. Co., Ltd. | NCT05949801 Evaluation of the Effect of Injectable Neucardin on Cardiac Function and Reversal Ventricular Remodeling in Patients With Chronic Systolic Heart Failure | Chronic Systolic Heart Failure | completed | 202 |
| 2024-08-30 | P2 | GlaxoSmithKline | NCT05960097 A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults | SARS-CoV-2; COVID-19 | completed | 692 |
| 2024-08-30 est. | P1/P2 | QureBio Ltd. | NCT05964543 The Safety and Efficacy of Q-1802 Combined With XELOX in Gastrointestinal Tumors | Gastroesophageal Junction (GEJ) Adenocarcinoma | unknown | 72 |
| 2024-08-30 | P1/P2 | GPN Vaccines | NCT05982314 Extension Safety and Immunogenicity Study of GPNV-001 | Pneumococcal Infections | completed | 60 |
| 2024-08-30 est. | P3 | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | NCT06314685 Immunogenicity and Safety of MCV4 in Volunteers Aged 6 Months-5 Years | Healthy Population | unknown | 2450 |
| 2024-08-30 | P2 | Ebima Clifford Okundaye | NCT06948292 Role of QRX-3 in Chronic Kidney Disease Patients in Outpatients Clinics | Chronic Kidney Disease Stages 3-5; Diabetic Kidney Disease; Hypertensive Kidney Disease | completed | 127 |
| 2024-08-31 | P1/P2 | Karyopharm Therapeutics Inc KPTIQ | NCT02649790 Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications | Relapsed/Refractory Multiple Myeloma (RRMM); Metastatic Colorectal Cancer (mCRC); Metastatic Castrat | completed | 277 |
| 2024-08-31 | P1/P2 | Bristol-Myers Squibb BMY | NCT03994601 An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers | Advanced Cancer | completed | 219 |
| 2024-08-31 | P3 | Sanofi Pasteur, a Sanofi Company SNY | NCT04904549 Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older | COVID-19 | terminated | 23670 |
| 2024-08-31 est. | P2 | Neurokine Therapeutics | NCT05194163 MW150 Stress Kinase Inhibitor in Mild to Moderate Alzheimer's Disease | Alzheimer Disease | unknown | 24 |
| 2024-08-31 | P1/P2 | TransThera Sciences (Nanjing), Inc. | NCT05253053 To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors | Advanced Solid Tumor; Cholangiocarcinoma; Biliary Tract Cancer; HER2-negative Breast Cancer; Triple | completed | 84 |
| 2024-08-31 | P2 | SOTIO Biotech AG | NCT05256381 A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors | Non-Small Cell Lung Cancer; Colorectal Cancer; Cutaneous Squamous Cell Carcinoma; Hepatocellular Car | terminated | 166 |
| 2024-08-31 est. | P2 | Orthocare Innovations, LLC | NCT05619484 Smart Ankle-Foot Orthosis to Improve Stroke Outcomes: Smart AFO | Stroke | unknown | 50 |
| 2024-08-31 est. | P2 | Clairvoyant Therapeutics | NCT05646303 Psilocybin-Assisted Psychotherapy in Adults With Alcohol Use Disorder (AUD) | Alcohol Use Disorder | unknown | 128 |
| 2024-08-31 | P1/P2 | InxMed (Shanghai) Co., Ltd. | NCT05830539 IN10018 Combination Therapy in Previously-treated Locally Advanced or Metastatic Solid Tumor Patients | Locally Advanced or Metastatic Solid Tumors | completed | 68 |
| 2024-08-31 est. | P1/P2 | Luye Pharma Group Ltd. | NCT05865925 Safety, Tolerability, Pharmacokinetics (PK), and Primary Clinical Efficacy of LY01616 in Patients With Advanced Solid Tumors | Advanced Solid Tumors | unknown | 78 |
| 2024-08-31 | P2 | PT Bio Farma | NCT05933278 Homologous Booster Study of COVID-19 Protein Subunit Recombinant Vaccine | COVID-19 | completed | 150 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.